Work

Abstract CT236: ELCIN: Elacestrant (Ela) in women and men with CDK4/6 inhibitor (CDK4/6i)- naive estrogen receptor- positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC): An open-label multicenter phase 2 study

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct236

Authors: Virginia Kaklamani, Giorgi Dzagnidze, Nicoleta Zenovia Antone, Anu R. Thummala, Mikheil Janjalia, Patricia Santi, Carlos Barrios, Mehmet Ali Sendur, Xiaoling Zhang, Angela Gambioli, Manuel Dominguez, Kathy Puyana Theall, Tomer Wasserman, William J. Gradishar

Institutions: The University of Texas at San Antonio Health Science Center, Institute of Oncology Prof. Dr. Ion Chiricuta, Comprehensive Cancer Centers of Nevada, National Cancer Center of Georgia, Latin American Cooperative Oncology Group (LACOG), İstanbul Başakşehir Çam ve Sakura Şehir Hastanesi, Menarini Group (Italy), Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409821784

Cites:

Cited by:

Related to: 10